IMPORTANT INFORMATION 
DETERMINATION OF FETAL SEX BY ANALYSIS OF CIRCULATING DNA
CHANGES : PRE-ANALYTICAL CONDITIONS

Dear colleague,

In order to simplify the pre-analytical procedure, this test will now be carried out using plasma rather than serum as previously. It will therefore no longer be necessary for the sample to be pre-treated (centrifuged) by your laboratory before it is sent out.
The maternal blood sample will be taken in a Streck-Cell-Free DNA BCT® tube and sent directly to our laboratory at room temperature (maximum storage time 5 days; temporary storage at +4°C if necessary).

This device is identical to the one used for the screening test for chromosomal abnormalities by analysis of circulating DNA (DPNI). It enables the blood sample to be stored properly (stabilisation of fetal DNA) without the need for prior handling.

Available to order from www.mycerba.com

These new pre-analytical conditions therefore simplify and harmonise practices for the analysis of circulating fetal DNA.
However, the documentation that must be attached to the sample remains unchanged: the medical prescription form, including consent for the test to be carried out, and the ultrasound report.

Please note! From Tuesday 2 January, serum samples will be refused.

Please do not hesitate to contact us should you require any further information,

Cerba Customer Relations Department
intgb@lab-cerba.com